Mounjaro (tirzepatide) is a prescription medication licensed in the UK for managing type 2 diabetes mellitus in adults. As a dual GIP and GLP-1 receptor agonist, it offers a unique mechanism for improving blood glucose control. Whilst Mounjaro is available through NHS pathways for eligible patients, private online pharmacies such as Medino provide an alternative route to access this treatment. Understanding the Medino Mounjaro cost, including consultation fees, medication pricing, and ongoing expenses, is essential for patients considering private diabetes care. This article explores how to access Mounjaro through Medino, compares NHS and private options, and outlines the financial commitment involved in private tirzepatide therapy.

What Is Mounjaro and What Is It Used For?

Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes mellitus in adults.^[1] It belongs to a class of medications known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This dual mechanism of action distinguishes Mounjaro from other diabetes treatments, as it targets two incretin hormone pathways simultaneously to improve blood glucose control.

The medication works by enhancing insulin secretion when blood glucose levels are elevated, suppressing glucagon release (which reduces glucose production by the liver), and slowing gastric emptying. These combined effects help to lower blood sugar levels and improve glycaemic control. While tirzepatide has been associated with significant weight reduction, which can be beneficial for patients with type 2 diabetes who are overweight or obese, Mounjaro is specifically licensed for diabetes management, not as a weight loss treatment.

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled pen device. The treatment begins with a 2.5 mg once-weekly dose for 4 weeks, which is an initiation dose not intended for long-term glycaemic control. After this initial period, the dose is increased to 5 mg once weekly, with potential further increases at intervals of at least 4 weeks (to 7.5 mg, 10 mg, 12.5 mg, and up to a maximum of 15 mg weekly) based on individual response and tolerability. Mounjaro is indicated as an adjunct to diet and exercise, and should form part of a comprehensive diabetes management plan.

Important safety considerations include risk of pancreatitis (seek urgent medical attention for severe abdominal pain), gallbladder disease, dehydration due to gastrointestinal effects, and potential worsening of diabetic retinopathy, particularly with rapid improvements in blood glucose.^[1][11] When used with insulin or sulfonylureas, dose adjustments of these medications may be needed to reduce hypoglycaemia risk. Tirzepatide can reduce the effectiveness of oral contraceptives, so additional contraceptive methods are recommended for 4 weeks after starting treatment or increasing the dose.^[1] Mounjaro should not be used during pregnancy or when trying to conceive.^[1]

Patients should always use Mounjaro under the supervision of a healthcare professional experienced in diabetes management and report any suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

How to Access Mounjaro Through Medino

Medino is a UK-registered online pharmacy that offers patients the option to access prescription medications, including Mounjaro, through a regulated private healthcare pathway. To obtain Mounjaro via Medino, patients must complete an online consultation process that ensures the medication is clinically appropriate and safe for their individual circumstances.

The consultation typically involves completing a detailed medical questionnaire covering your medical history, current medications, diabetes management, and any relevant health conditions. This information is reviewed by a registered UK prescriber (either a GP or an independent prescribing pharmacist) who will assess whether Mounjaro is suitable for you. If approved, a private prescription is issued and the medication can be dispensed and delivered directly to your home address.

It is essential to understand that Medino operates as a private healthcare service, meaning consultations and prescriptions are provided outside the NHS framework. Patients using this service will be responsible for the full cost of both the consultation and the medication. The online consultation process follows General Medical Council and General Pharmaceutical Council standards for remote prescribing, with appropriate monitoring and safety protocols in place.

Before starting treatment through Medino or any private provider, patients should consider discussing their diabetes management with their NHS GP or diabetes specialist nurse. This ensures continuity of care and allows your regular healthcare team to monitor your overall diabetes control, adjust other medications if necessary, and conduct appropriate blood tests (such as HbA1c monitoring). It is advisable to share information about your private prescriptions with your NHS healthcare team to avoid potential medication interactions or duplication of treatments.

Patients should never stop or alter their existing diabetes medications without medical advice, as this could lead to dangerous fluctuations in blood glucose levels. You will also need training on how to administer the injection correctly and arrangements for safe disposal of used needles via a sharps bin.

It's important to note that there are currently supply constraints affecting GLP-1 receptor agonists, including tirzepatide, across both NHS and private sectors in the UK.^[5] This may affect availability and waiting times for treatment.

NHS vs Private Mounjaro: Understanding Your Options

Understanding the difference between NHS and private access to Mounjaro is crucial for making an informed decision about your diabetes treatment. On the NHS, access to Mounjaro is determined by NICE Technology Appraisal guidance for tirzepatide. Following a positive NICE recommendation, NHS organisations are required to fund and provide the treatment for eligible patients within the implementation timeframe, though local service arrangements and current supply constraints may affect how quickly you can access it.

NHS prescribing of Mounjaro generally requires assessment by a diabetes specialist or GP with expertise in diabetes management. Patients will undergo comprehensive evaluation including blood tests (HbA1c, renal function, lipid profile), review of current medications, and assessment of cardiovascular risk factors. NICE criteria typically specify who is eligible for treatment, including HbA1c thresholds and previous treatment history, with continuation rules based on glycaemic response and weight loss.

If prescribed through the NHS, the medication cost is covered by standard prescription charges (currently £9.90 per item in England, though charges are reviewed annually). Prescriptions are free in Scotland and Wales, and currently free in Northern Ireland.^[4] Many patients with diabetes are exempt from prescription charges in England through medical exemption certificates.^[4]

In contrast, private access through services like Medino offers potentially faster access but at significantly higher cost. Private prescribing does not require referral to a specialist and can be initiated following an online consultation. However, patients bear the full cost of the medication, which can be substantial (typically several hundred pounds per month). Private treatment also means you are responsible for ensuring appropriate monitoring, though reputable providers will require regular review consultations.

Regardless of which route you choose, regular monitoring is essential, including HbA1c (every 3-6 months), renal function, weight, and assessment for hypoglycaemia risk (particularly if you take insulin or sulfonylureas). Diabetic retinopathy screening is also important, especially when starting treatments that rapidly improve blood glucose control.

Key considerations when choosing between NHS and private access include: your current diabetes control and treatment history, financial circumstances, urgency of treatment need, and the importance of integrated care within the NHS diabetes service. It is advisable to maintain open communication with your NHS diabetes team regardless of which route you choose, ensuring comprehensive oversight of your condition. Be aware that ongoing national supply constraints for GLP-1 receptor agonists may affect availability through both NHS and private routes.

Mounjaro Cost at Medino: Pricing and Payment Options

The cost of Mounjaro through Medino reflects private healthcare pricing and includes both the consultation fee and the medication itself. As of early 2024, patients should expect to pay approximately £150–£250 per month for Mounjaro treatment, though exact pricing may vary depending on the prescribed dose, current supply availability, and any promotional offers. This cost typically includes the initial online consultation, prescription, and one month's supply of medication (four pre-filled pens for once-weekly dosing), but you should verify exactly what is included with the provider.

It is important to note that Mounjaro treatment is generally intended as a long-term therapy for type 2 diabetes management. Therefore, patients considering private access should carefully evaluate the ongoing financial commitment, which could amount to £1,800–£3,000 or more annually. Some private providers, including Medino, may offer subscription or instalment payment plans to help spread the cost, making treatment more financially manageable. Patients should enquire directly about available payment options and any terms and conditions associated with subscription services.

Additional costs to consider include follow-up consultations (usually required every 3–6 months to review treatment response and safety), blood tests for monitoring (HbA1c, renal function), and potential dose adjustments. While some providers include follow-up consultations in their pricing structure, others may charge separately. Patients should clarify the total cost of care, not just the medication price, before committing to private treatment.

National supply constraints affecting GLP-1 receptor agonists may impact both availability and pricing in the private sector. These shortages are expected to continue for some time, so patients should discuss potential supply issues with their provider.

For those finding private costs prohibitive, it is worth discussing NHS access options with your GP or diabetes specialist nurse. If you meet NICE criteria for tirzepatide therapy, you may be eligible for NHS prescribing at standard prescription charges (or free if you qualify for exemption). Additionally, patients experiencing financial hardship should never compromise their diabetes management—speak to your healthcare team about alternative treatment options that may be more affordable while still providing effective glycaemic control. Patient safety and appropriate diabetes management should always take precedence over treatment cost considerations.

If you experience any suspected side effects while using Mounjaro, report them to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk) and seek urgent medical attention for serious reactions.

Frequently Asked Questions